• 1. Department of Radiation Oncology, the Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, P.R.China;
  • 2. Department of Obstetrics and Gynecology, Quanzhou Medical College People’s Hospital Affiliated, Quanzhou, 362000, P.R.China;
ZHENG Jianqing, Email: 18060108268@189.cn
Export PDF Favorites Scan Get Citation

Objectives To compare the efficacy and safety of weekly nedaplatin compared with weekly cisplatin as postoperative concurrent chemoradiotherapy scheme for cervical cancer patients.Methods This trial was performed in the Department of Radiation Oncology in the Second Affiliated Hospital of Fujian Medical University from June 2016 to January 2017. A total of 200 patients with stage ⅠB1-ⅡB cervical cancer were randomly assigned to the nedaplatin group and the cisplatin group after signing informed content. The dose of nedaplatin or cisplatin ranged 35 to 40 mg/m2, once a week for 5 weeks. Intensity-modulated radiation therapy or three-dimensional conformal radiation therapy were used for patients. The progression-free survival, overall survival and adverse reactions were compared between two groups. Statistical analysis was performed by SPSS 24.0 software.Results A total of 105 patients were enrolled in the nedaplatin group, and 95 patients were in cisplatin group. The three-year progression-free survival rate was 80.5% vs. 79.5% in the nedaplatin group and the cisplatin group, respectively; and no statistical significant difference was found (χ2=0.198, P=0.656) between two groups. The 3-year overall survival rates were 72.5% and 69.9% for the nedaplatin group and the cisplatin group, respectively, and there was no significant difference between the two groups (χ2=0.261, P=0.609). The incidence of grade 3/4 nausea and vomiting in the nedaplatin group was 6.67%, which was significantly lower than that of 15.79% in the cisplatin group, and statistical significant difference was found (χ2=2.555, P=0.011); however, the incidence of grade 3/4 thrombocytopenia in the nedaplatin group was 9.52%, which was significantly higher than that in the cisplatin group (3.15%); and the difference was statistically significant (χ2=1.985, P=0.047). There was no difference in the incidence of adverse reactions such as anemia, neutropenia, and radiological proctitis in both groups.Conclusions Nedaplatin-based concurrent chemoradiotherapy has similar efficacy compared to cisplatin-based concurrent chemoradiotherapy, and it could significantly reduce the digestive tract reaction, which can be used as an alternative to cisplatin.

Citation: XIAO Lihua, HUANG Bifen, ZHENG Jianqing, CHEN Mingfen, SU Jingjing, WU Min. Weekly nedaplatin versus weekly cisplatin as postoperative concurrent chemoradiotherapy after radical surgery for cervical cancer: a randomized controlled trial. Chinese Journal of Evidence-Based Medicine, 2019, 19(4): 381-386. doi: 10.7507/1672-2531.201807055 Copy

  • Previous Article

    Interpretation of European Respiratory Society statement on obstructive sleep disordered breathing in 1 to 23-month-old children
  • Next Article

    Liver dysfunction during pregnancy in 35 452 pregnancy women and its association with premature birth: a prospective cohort study